---
schema_version: "secwatch.filing_event.v1"
accession: "0001516551-25-000050"
form_type: "8-K"
ticker: "SKYE"
cik: "0001516551"
company_name: "Skye Bioscience, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:29:09.398769+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Skye Bioscience Q2 net loss $17.6M; Phase 2a top-line data due late Q3/early Q4 2025

## Summary
- Net loss of $17.6M for Q2 2025, vs $7.9M in Q2 2024; R&D expense rose to $14.3M from $4.1M.
- Cash, equivalents & short-term investments $48.6M as of June 30, 2025; expected to fund operations through at least Q1 2027.
- Phase 2a CBeyond study of nimacimab top-line data expected late Q3/early Q4 2025; extension study enrolling.
- Preclinical data: nimacimab + low-dose tirzepatide boosted weight loss beyond optimal tirzepatide; nimacimab reduced post-treatment weight rebound.

## SEC filing metadata
- accession: 0001516551-25-000050
- form_type: 8-K
- ticker: SKYE
- cik: 0001516551
- company_name: Skye Bioscience, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1516551/000151655125000050/0001516551-25-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1516551/000151655125000050/skye-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001516551-25-000050
- JSON: https://secwatch.observer/filing/0001516551-25-000050.json
- Plain text: https://secwatch.observer/filing/0001516551-25-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.